Work

Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.5545

Authors: Rachel N. Grisham, Evis Sala, Qin Zhou, Alexia Iasonos, Deborah DeLair, Gopa Iyer, David Michael Hyman, David R. Spriggs, Carol Aghajanian

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2592478480

Cites:

Cited by:

Related to: 10